Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Allovir, Inc. | alvr-ex322_6.htm |
| EX-32.1 - EX-32.1 - Allovir, Inc. | alvr-ex321_7.htm |
| EX-31.2 - EX-31.2 - Allovir, Inc. | alvr-ex312_8.htm |
| EX-31.1 - EX-31.1 - Allovir, Inc. | alvr-ex311_9.htm |
| EX-10.20 - EX-10.20 - Allovir, Inc. | alvr-ex1020_1061.htm |
| EX-10.19 - EX-10.19 - Allovir, Inc. | alvr-ex1019_1062.htm |
| EX-10.18 - EX-10.18 - Allovir, Inc. | alvr-ex1018_1063.htm |
| EX-10.17 - EX-10.17 - Allovir, Inc. | alvr-ex1017_627.htm |
| EX-4.2 - EX-4.2 - Allovir, Inc. | alvr-ex42_626.htm |
| 10-K - 10-K - Allovir, Inc. | alvr-10k_20201231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement No. 333-240259 on Form S-8 of our report dated February 12, 2021 relating to the financial statements of AlloVir, Inc. appearing in this Annual Report on Form 10-K of AlloVir, Inc. for the year ended December 31, 2020.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
February 12, 2021